Researchers are uncovering how disrupted glutamatergic synapses drive diverse forms of intellectual disability, revealing new ...

For decades, dopamine has been celebrated in neuroscience as the quintessential "reward molecule"—a chemical herald of ...

Phase 2b (CBeyond 2) plan to be finalized in Q1; trial launch targeted for Q3 2026.

GRIN Therapeutics begins patient dosing in global phase 3 Beeline trial of investigational radiprodil for GRINRelated neurodevelopmental disorder: New York Monday, January 12, 202 ...

GRIN Therapeutics, Inc., a leader in the development of targeted disease-specific therapies for serious neurodevelopmental disorders, today announced that it has dosed the first patient in its global ...

iOnctura CEO to present at the 2026 J.P. Morgan Healthcare Conference -- Participation underscores growing excitement around company's momentum and potential in precision oncology ...

Addex spin-out Neurosterix begins phase 1 study with M4 PAM - NTX-253 for schizophrenia: Geneva, Switzerland Thursday, January 8, 2026, 12:00 Hrs [IST] Addex Therapeutics, a clini ...

Ad Hoc Announcement Pursuant to Art.?53 LR Geneva, Switzerland, January 7, 2026 - Addex Therapeutics(SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing ...

Neurosterix was spun-out of Addex in April 2024, raising $65 million in a Series A financing led by funds affiliated with ...

Multiple clinical data readouts expected in 2026 present opportunity for substantial value creation KOASTAL-2 and -3 on track for consolidated topline readout in the second quarter of 2026 Plans to co ...

Multiple clinical data readouts expected in 2026 present opportunity for substantial value creationKOASTAL-2 and -3 on track for consolidated ...

Detailed price information for Xoma Corp 8.625% (XOMAP-Q) from The Globe and Mail including charting and trades.